Biochemical diagnosis of Sanfilippo disorder types A and B.
Mucopolysaccharidosis
N-alpha-acetylglucosaminidase enzymes
N-sulphoglucosamine sulphohydrolase
Sanfilippo disorder
Journal
Journal, genetic engineering & biotechnology
ISSN: 2090-5920
Titre abrégé: J Genet Eng Biotechnol
Pays: Netherlands
ID NLM: 101317150
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
received:
13
01
2023
accepted:
01
11
2023
medline:
10
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
One of the 11 recognized mucopolysaccharidosis (MPS) diseases is Sanfilippo. It is autosomal recessive in its mode of transmission. There are four subtypes of Sanfilippo (A, B, C, and D). The most worldwide prevalent subtypes of mucopolysaccharidosis type III (MPS III) are A and B followed by C and D subtypes. To estimate the frequency of MPS IIIA among MPS III patients, we diagnose and compare their clinical features with those of MPS IIIB and also compare the prevalence of MPS IIIB versus MPS IIIA among diagnosed cases at the Biochemical Genetic Department at NRC. For every case that was referred, the quantitative determination of urine Glycosaminoglycans (GAGs) was assessed. Two-dimensional electrophoresis (2DE) of GAGs extracted from urine was performed on all cases with high urinary GAG levels. Both N-sulphoglucosamine sulphohydrolase (MPS IIIA) and N-alpha-acetylglucosaminidase (MPS IIIB) enzyme activity were determined fluorometrically. From November 2019 to May 2022, 535 cases were referred to the National Research Centre's Biochemical Genetics Department. 233 (43%) MPS cases were diagnosed with high urinary GAG levels for their ages. 73 (31.3%) MPS III cases were diagnosed by 2DE out of the 233 MPS cases. Plasma N-alpha-acetylglucosaminidase enzyme assay was insufficient in 36 (49.3%) patients (Sanfilippo type B), while N-sulphoglucosamine sulphohydrolase enzyme activity was deficient in 15 (20.6%) patients. The other 22 (30.1%) patients are either Sanfilippo type C or D. N-sulphoglucosamine sulphohydrolase enzyme activity was measured for the first time in Egypt. Thirty-one percent of all diagnosed MPS cases during the last 3 years were MPS type III, making Sanfilippo the most common MPS type among the referred cases to our Biochemical Genetics Department. MPS IIIA accounts for 20.6% of MPSIII cases in this study. Still, MPS type IIIB is the commonest type among diagnosed patients.
Sections du résumé
BACKGROUND
BACKGROUND
One of the 11 recognized mucopolysaccharidosis (MPS) diseases is Sanfilippo. It is autosomal recessive in its mode of transmission. There are four subtypes of Sanfilippo (A, B, C, and D). The most worldwide prevalent subtypes of mucopolysaccharidosis type III (MPS III) are A and B followed by C and D subtypes. To estimate the frequency of MPS IIIA among MPS III patients, we diagnose and compare their clinical features with those of MPS IIIB and also compare the prevalence of MPS IIIB versus MPS IIIA among diagnosed cases at the Biochemical Genetic Department at NRC. For every case that was referred, the quantitative determination of urine Glycosaminoglycans (GAGs) was assessed. Two-dimensional electrophoresis (2DE) of GAGs extracted from urine was performed on all cases with high urinary GAG levels. Both N-sulphoglucosamine sulphohydrolase (MPS IIIA) and N-alpha-acetylglucosaminidase (MPS IIIB) enzyme activity were determined fluorometrically.
RESULTS
RESULTS
From November 2019 to May 2022, 535 cases were referred to the National Research Centre's Biochemical Genetics Department. 233 (43%) MPS cases were diagnosed with high urinary GAG levels for their ages. 73 (31.3%) MPS III cases were diagnosed by 2DE out of the 233 MPS cases. Plasma N-alpha-acetylglucosaminidase enzyme assay was insufficient in 36 (49.3%) patients (Sanfilippo type B), while N-sulphoglucosamine sulphohydrolase enzyme activity was deficient in 15 (20.6%) patients. The other 22 (30.1%) patients are either Sanfilippo type C or D.
CONCLUSION
CONCLUSIONS
N-sulphoglucosamine sulphohydrolase enzyme activity was measured for the first time in Egypt. Thirty-one percent of all diagnosed MPS cases during the last 3 years were MPS type III, making Sanfilippo the most common MPS type among the referred cases to our Biochemical Genetics Department. MPS IIIA accounts for 20.6% of MPSIII cases in this study. Still, MPS type IIIB is the commonest type among diagnosed patients.
Identifiants
pubmed: 37947910
doi: 10.1186/s43141-023-00586-7
pii: 10.1186/s43141-023-00586-7
pmc: PMC10638229
doi:
Types de publication
Journal Article
Langues
eng
Pagination
112Informations de copyright
© 2023. The Author(s).
Références
Clin Chem. 1992 Jun;38(6):803-7
pubmed: 1597005
Tunis Med. 2009 Nov;87(11):782-5
pubmed: 20209839
Pediatrics. 2005 Jun;115(6):e681-9
pubmed: 15930196
J Inherit Metab Dis. 2014 May;37(3):431-7
pubmed: 24271936
Mol Genet Metab. 2011 Jan;102(1):49-56
pubmed: 20934363
Heliyon. 2021 Aug 19;7(8):e07830
pubmed: 34471711
Cleft Palate J. 1970 Apr;7:578-94
pubmed: 5270507
Pediatr Int. 2015 Jun;57(3):331-8
pubmed: 25851924
Clin Chem. 1989 Jul;35(7):1472-7
pubmed: 2503262
Orphanet J Rare Dis. 2019 Nov 12;14(1):249
pubmed: 31718697
Mol Diagn Ther. 2019 Apr;23(2):291-299
pubmed: 30712216
J Hum Genet. 2020 Jul;65(7):557-567
pubmed: 32277174
J Clin Diagn Res. 2016 Nov;10(11):SC05-SC08
pubmed: 28050459
Ann Neurol. 2010 Dec;68(6):876-87
pubmed: 21061399
Biochem Res Int. 2012;2012:471325
pubmed: 22013531
J Inherit Metab Dis. 1996;19(3):278-85
pubmed: 8803769
Hum Genet. 2000 Dec;107(6):568-76
pubmed: 11153910
Int J Mol Sci. 2020 Feb 13;21(4):
pubmed: 32070051
Orphanet J Rare Dis. 2016 Sep 15;11(1):126
pubmed: 27629047
J Inherit Metab Dis. 1988;11(1):17-29
pubmed: 3128685
Cardiol Young. 2009 Apr;19(2):170-8
pubmed: 19195419
Brain Dev. 2001 Oct;23(6):385-9
pubmed: 11578848
J Neurochem. 2023 Aug;166(3):481-496
pubmed: 37357981
J Inherit Metab Dis. 2021 Jan;44(1):129-147
pubmed: 32944950
J Clin Invest. 2023 Jan 17;133(2):
pubmed: 36413418
Heart. 2016 Aug 15;102(16):1257-62
pubmed: 27102649
J Inherit Metab Dis. 2005;28(2):187-202
pubmed: 15877208
PLoS One. 2012;7(4):e35787
pubmed: 22558223
Orphanet J Rare Dis. 2022 Oct 27;17(1):391
pubmed: 36303195
Am J Med Genet A. 2011 Jan;155A(1):58-68
pubmed: 21204211
Arch Neurol. 2007 Nov;64(11):1629-34
pubmed: 17998446
Neurotherapeutics. 2023 Jan;20(1):254-271
pubmed: 36344724
East Mediterr Health J. 2001 Nov;7(6):981-91
pubmed: 15332740
Neural Regen Res. 2024 Feb;19(2):355-359
pubmed: 37488890
JIMD Rep. 2013;10:1-9
pubmed: 23430803
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Genet Test Mol Biomarkers. 2012 Aug;16(8):846-9
pubmed: 22480138
Orphanet J Rare Dis. 2023 Mar 13;18(1):52
pubmed: 36907859